Profound Medical (TSE:PRN) has released an update.
Profound Medical Corp. has successfully held its Annual General Meeting where all six board director nominees were elected with high approval rates, and the reappointment of PricewaterhouseCoopers LLP as the company’s auditor was confirmed. The meeting showcased Profound’s strong shareholder support, representing over 62% of outstanding shares. Profound, a medical device company, continues to make strides in commercializing innovative, incision-free therapies for diseased tissue ablation, with products like TULSA-PRO and Sonalleve already approved by various international regulatory agencies.
For further insights into TSE:PRN stock, check out TipRanks’ Stock Analysis page.
